Drug Patent Watch
DECEMBER 9, 2021
This chart shows the pharmaceutical companies with the most concentrate dosed drugs. For a different perspective, see the most popular dosage types. The companies with the most concentrate dosed drugs…. The post Which pharmaceutical companies have the most concentrate dosed drugs? appeared first on DrugPatentWatch - Make Better Decisions.
Drug Channels
DECEMBER 7, 2021
It’s time for our annual deep dive into employer-sponsored coverage for prescription drugs. For 2021, employers backed away slightly from high-deductible health plans. However, their pharmacy benefit designs increased the use of coinsurance for specialty and fourth-tier drugs. These designs have significantly raised patients’ out-of-pocket obligations and are likely to have reduced adherence.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
EG Life Sciences
DECEMBER 6, 2021
For some time, Eliassen Group and EG Life Sciences have been working together to tackle the challenges faced by pharmaceutical companies as they innovate to keep up with a rapidly changing landscape. As part of that, we have invited members of the pharmaceutical industry and Agile experts to lean coffees that discuss ways to bring Agile and biopharma together to speed up delivery, unlock operational excellence, and improve lives.
The Pharma Data
DECEMBER 4, 2021
TEL AVIV & PARSIPPANY, N.J.–(BUSINESS WIRE)– Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the launch of an authorized generic of Epiduo® 1 Forte Gel (adapalene and benzoyl peroxide gel 0.3%/2.5%), in the United States. Adapalene and benzoyl peroxide gel 0.3%/2.5% is a topical prescription medicine used to treat acne vulgaris.
Speaker: Simran Kaur, Co-founder & CEO at Tattva.Health
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
Drug Patent Watch
DECEMBER 9, 2021
Annual Drug Patent Expirations for PROAIR+RESPICLICK Proair Respiclick is a drug marketed by Teva Branded Pharm and is included in one NDA. It is available from two suppliers. There are…. The post New patent for Teva Branded drug PROAIR RESPICLICK appeared first on DrugPatentWatch - Make Better Decisions.
Drug Discovery Digest brings together the best content for drug research and development professionals from the widest variety of industry thought leaders.
Olympian Clinical Research
DECEMBER 7, 2021
The clinical trial process can be a complicated but rewarding one. There are many different types of trials and even more ways to participate in them. Therefore, fully understanding the clinical trial process can help you get the most out of any study that you choose to participate in. What is a Clinical Trial? A clinical trial is a medical research study designed to provide data for new and existing treatment methods.
The Pharma Data
DECEMBER 4, 2021
GlaxoSmithKline (GSK) plc moment launched Target the Future, an transnational,multi-year action devoted to advancing invention and addressing crucial requirements in the multiple myeloma community. The programme will give education on progress in the field of multiple myeloma, identify crucial challenges the community faces, and grease results to help produce a better future for cases, their caregivers and loved bones.
Drug Patent Watch
DECEMBER 8, 2021
This chart shows the drugs with the most patents in Eurasian Patent Organization. Patents must be filed in each country (or, in some cases regional patent office) where patent protection…. The post Which pharmaceutical drugs have the most drug patents in Eurasian Patent Organization? appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
DECEMBER 6, 2021
This chart shows the pharmaceutical companies with the most cream dosed drugs. For a different perspective, see the most popular dosage types. The companies with the most cream dosed drugs…. The post Which pharmaceutical companies have the most cream dosed drugs? appeared first on DrugPatentWatch - Make Better Decisions.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Drug Patent Watch
DECEMBER 9, 2021
Annual Drug Patent Expirations for PROAIR+DIGIHALER Proair Digihaler is a drug marketed by Teva Branded Pharm and is included in one NDA. It is available from two suppliers. There are…. The post New patent for Teva Branded drug PROAIR DIGIHALER appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
DECEMBER 9, 2021
Annual Drug Patent Expirations for ARMONAIR+DIGIHALER Armonair Digihaler is a drug marketed by Teva Pharm and is included in one NDA. It is available from one supplier. There are twenty-three…. The post New patent for Teva Pharm drug ARMONAIR DIGIHALER appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
DECEMBER 9, 2021
Annual Drug Patent Expirations for ARMONAIR+RESPICLICK Armonair Respiclick is a drug marketed by Teva Pharm and is included in one NDA. It is available from one supplier. There are thirty-one…. The post New patent for Teva Pharm drug ARMONAIR RESPICLICK appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
DECEMBER 9, 2021
Annual Drug Patent Expirations for UPTRAVI Uptravi is a drug marketed by Actelion and is included in two NDAs. It is available from one supplier. There are six patents protecting…. The post New patent for Actelion drug UPTRAVI appeared first on DrugPatentWatch - Make Better Decisions.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Drug Patent Watch
DECEMBER 9, 2021
Annual Drug Patent Expirations for AIRDUO+DIGIHALER Airduo Digihaler is a drug marketed by Teva Pharm and is included in one NDA. It is available from four suppliers. There are twenty-six…. The post New patent for Teva Pharm drug AIRDUO DIGIHALER appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
DECEMBER 9, 2021
Annual Drug Patent Expirations for GIAPREZA Giapreza is a drug marketed by La Jolla Pharma and is included in one NDA. It is available from one supplier. There are nine…. The post New patent for La Jolla drug GIAPREZA appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
DECEMBER 9, 2021
Annual Drug Patent Expirations for VUITY Vuity is a drug marketed by Abbvie Inc and is included in one NDA. It is available from one supplier. The generic ingredient in…. The post New patent for Abbvie Inc drug VUITY appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
DECEMBER 9, 2021
Annual Drug Patent Expirations for AIRDUO+RESPICLICK Airduo Respiclick is a drug marketed by Teva Pharm and is included in one NDA. It is available from four suppliers. There are twenty-one…. The post New patent for Teva Pharm drug AIRDUO RESPICLICK appeared first on DrugPatentWatch - Make Better Decisions.
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
Drug Patent Watch
DECEMBER 6, 2021
Annual Drug Patent Expirations for CRESEMBA Cresemba is a drug marketed by Astellas and is included in two NDAs. It is available from one supplier. There is one patent protecting…. The post New patent for Astellas drug CRESEMBA appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
DECEMBER 6, 2021
Annual Drug Patent Expirations for NERLYNX Nerlynx is a drug marketed by Puma Biotech and is included in one NDA. It is available from one supplier. There are ten patents…. The post New patent for Puma Biotech drug NERLYNX appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
DECEMBER 6, 2021
Annual Drug Patent Expirations for SPRITAM Spritam is a drug marketed by Aprecia Pharms and is included in one NDA. It is available from one supplier. There are two patents…. The post New patent for Aprecia Pharms drug SPRITAM appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
DECEMBER 6, 2021
Annual Drug Patent Expirations for XATMEP Xatmep is a drug marketed by Azurity and is included in one NDA. It is available from one supplier. There are four patents protecting…. The post New patent for Azurity drug XATMEP appeared first on DrugPatentWatch - Make Better Decisions.
Advertisement
Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic
Drug Patent Watch
DECEMBER 6, 2021
Annual Drug Patent Expirations for QBRELIS Qbrelis is a drug marketed by Azurity and is included in one NDA. It is available from one supplier. There are seven patents protecting…. The post New patent for Azurity drug QBRELIS appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
DECEMBER 5, 2021
This chart shows the pharmaceutical companies with the most implant dosed drugs. For a different perspective, see the most popular dosage types. The companies with the most implant dosed drugs…. The post Which pharmaceutical companies have the most implant dosed drugs? appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
DECEMBER 5, 2021
Annual Drug Patent Expirations for OFIRMEV Ofirmev is a drug marketed by Mallinckrodt Hosp and is included in one NDA. It is available from two suppliers. There are five patents…. The post New patent expiration for Mallinckrodt Hosp drug OFIRMEV appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
DECEMBER 4, 2021
This chart shows the drugs with the most patents in European Patent Office. Patents must be filed in each country (or, in some cases regional patent office) where patent protection…. The post Which pharmaceutical drugs have the most drug patents in European Patent Office? appeared first on DrugPatentWatch - Make Better Decisions.
The Pharma Data
DECEMBER 4, 2021
The first peer-reviewed study in North America examining the timing between the first and second doses of COVID-19 mRNA vaccines shows that a longer dose interval leads to a stronger immune response. The study is funded by the Government of Canada through its COVID-19 Immunity Task Force (CITF). Principal investigator Dr. Brian Grunau, Assistant Professor in UBC’s Department of Emergency Medicine and Scientist at the Centre for Health Evaluation and Outcome Sciences, indicates that these r
Expert insights. Personalized for you.
98 
Let's personalize your content